

JAN 19 2018

---

# A BILL FOR AN ACT

RELATING TO THE MEDICAL USE OF CANNABIS.

**BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:**

1       SECTION 1. The legislature finds that the authority to  
2       accept the medical use of controlled substances rests with the  
3       states, which is why the State of Hawaii was able to accept the  
4       medical use of cannabis in 2000 and create a state regulated  
5       medical use of cannabis program.

6       The legislature also finds that the state scheduling of  
7       cannabis as a controlled substance does not apply to the medical  
8       use of cannabis in Hawaii, because patients are able to engage  
9       in the medical use of cannabis without facing the criminal  
10      penalties associated with the unlawful acquisition, use,  
11      possession, cultivation, distribution, and transportation of a  
12      controlled substance, and because moving cannabis into a  
13      different state schedule does not alter the medical use of  
14      cannabis in Hawaii.

15      The legislature also finds that the federal scheduling of  
16      cannabis as a controlled substance does not apply to the medical  
17      use of cannabis in Hawaii because the medical use of cannabis in



1 Hawaii is currently accepted medical use in treatment in the  
2 United States, and because moving cannabis into a different  
3 federal schedule does not alter the medical use of cannabis in  
4 Hawaii.

5 The purpose of this Act is to recognize that the state and  
6 federal scheduling of cannabis as a controlled substance does  
7 not apply to the medical use of cannabis in Hawaii, which  
8 clarifies the finding that Hawaii's medical use of cannabis  
9 program does not violate federal law.

10 SECTION 2. Section 329-14, Hawaii Revised Statutes, is  
11 amended to read as follows:

12 "§329-14 Schedule I. (a) The controlled substances  
13 listed in this section are included in schedule I.

14 (b) Any of the following opiates, including their isomers,  
15 esters, ethers, salts, and salts of isomers, esters, and ethers,  
16 unless specifically excepted, whenever the existence of these  
17 isomers, esters, ethers, and salts is possible within the  
18 specific chemical designation:

19 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-  
20 phenethyl)-4-piperidinyl]-N-phenylacetamide);

21 (2) Acetylmethadol;



- 1 (3) Allylprodine;
- 2 (4) Alphacetylmethadol (except levo-alphacetylmethadol,
- 3 levomethadyl acetate, or LAAM);
- 4 (5) Alphameprodine;
- 5 (6) Alphamethadol;
- 6 (7) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-
- 7 phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-
- 8 2-phenylethyl)-4-(N-propanilido) piperidine);
- 9 (8) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
- 10 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 11 (9) Benzethidine;
- 12 (10) Betacetylmethadol;
- 13 (11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
- 14 piperidinyl]-N-phenylpropanamide);
- 15 (12) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-
- 16 phenethyl)-3-methyl-4-piperidinyl]-N-
- 17 phenylpropanamide);
- 18 (13) Betameprodine;
- 19 (14) Betamethadol;
- 20 (15) Betaprodine;
- 21 (16) Clonitazene;



- 1 (17) Dextromoramide;
- 2 (18) Diampromide;
- 3 (19) Diethylthiambutene;
- 4 (20) Difenoquin;
- 5 (21) Dimenoxadol;
- 6 (22) Dimepheptanol;
- 7 (23) Dimethylthiambutene;
- 8 (24) Dioxaphetyl butyrate;
- 9 (25) Dipipanone;
- 10 (26) Ethylmethylthiambutene;
- 11 (27) Etonitazene;
- 12 (28) Etozeridine;
- 13 (29) Furethidine;
- 14 (30) Hydroxypethidine;
- 15 (31) Ketobemidone;
- 16 (32) Levomoramide;
- 17 (33) Levophenacymorphan;
- 18 (34) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
- 19 piperidyl]-N-phenylpropanamide);
- 20 (35) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-
- 21 4-piperidinyl]-N-phenylpropanamide);



- 1 (36) Morpheridine;
- 2 (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 3 (38) Noracymethadol;
- 4 (39) Norlevorphanol;
- 5 (40) Normethadone;
- 6 (41) Norpipanone;
- 7 (42) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-
- 8 phenethyl)-4-piperidinyl] propanamide;
- 9 (43) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine;
- 10 (44) Phenadoxone;
- 11 (45) Phenampromide;
- 12 (46) Phenomorphan;
- 13 (47) Phenoperidine;
- 14 (48) Piritramide;
- 15 (49) Proheptazine;
- 16 (50) Properidine;
- 17 (51) Propiram;
- 18 (52) Racemoramide;
- 19 (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
- 20 piperidinyl]-propanamide);
- 21 (54) Tilidine;



- 1 (55) Trimeperidine;
- 2 (56) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
- 3 (benzylfentanyl), its optical isomers, salts, and
- 4 salts of isomers;
- 5 (57) N-[1-(2-thienyl)methyl-4-piperidyl]-N-
- 6 phenylpropanamide (thenylfentanyl), its optical
- 7 isomers, salts, and salts of isomers;
- 8 (58) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,
- 9 (acetyl fentanyl), its optical, positional, and
- 10 geometric isomers, salts, and salts of isomers;
- 11 (59) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)
- 12 cyclohexylmethyl]benzamide), its isomers, esters,
- 13 ethers, salts, and salts of isomers, esters, and
- 14 ethers;
- 15 (60) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its
- 16 isomers, esters, ethers, salts, and salts of isomers,
- 17 esters, and ethers (Other names: Butyryl fentanyl);
- 18 (61) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-
- 19 yl]-N-phenylpropionamide, its isomers, esters, ethers,
- 20 salts, and salts of isomers, esters, and ethers (Other
- 21 names: beta-hydroxythiofentanyl);



(62) N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: Furanyl fentanyl); and

(63) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: U-47700).

(c) Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (1) Acetorphine;
- (2) Acetyldihydrocodeine;
- (3) Benzylmorphine;
- (4) Codeine methylbromide;
- (5) Codeine-N-Oxide;
- (6) Cyprenorphine;
- (7) Desomorphine;
- (8) Dihydromorphine;
- (9) Drotebanol;



- 1       (10)   Etorphine;
- 2       (11)   Heroin;
- 3       (12)   Hydromorphenol;
- 4       (13)   Methyldesorphine;
- 5       (14)   Methyldihydromorphine;
- 6       (15)   Morphine methylbromide;
- 7       (16)   Morphine methylsulfonate;
- 8       (17)   Morphine-N-Oxide;
- 9       (18)   Myrophine;
- 10      (19)   Nicocodeine;
- 11      (20)   Nicomorphine;
- 12      (21)   Normorphine;
- 13      (22)   Phoclodine; and
- 14      (23)   Thebacon.

15       (d)   Any material, compound, mixture, or preparation that  
16 contains any quantity of the following hallucinogenic  
17 substances, their salts, isomers, and salts of isomers, unless  
18 specifically excepted, whenever the existence of these salts,  
19 isomers, and salts of isomers is possible within the specific  
20 chemical designation:

- 21       (1)   Alpha-ethyltryptamine (AET);





- 1 (2) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 2 (3) 2,5-dimethoxyamphetamine (2,5-DMA);
- 3 (4) 3,4-methylenedioxy amphetamine;
- 4 (5) 3,4-methylenedioxymethamphetamine (MDMA);
- 5 (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-
- 6 MDA);
- 7 (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
- 8 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 9 (9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
- 10 (10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
- 11 (11) 3,4,5-trimethoxy amphetamine;
- 12 (12) Bufotenine;
- 13 (13) 4-methoxyamphetamine (PMA);
- 14 (14) Diethyltryptamine;
- 15 (15) Dimethyltryptamine;
- 16 (16) 4-methyl-2,5-dimethoxy-amphetamine;
- 17 (17) Gamma hydroxybutyrate (GHB) (some other names include
- 18 gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-
- 19 hydroxybutanoic acid; sodium oxybate; sodium
- 20 oxybutyrate);
- 21 (18) Ibogaine;



- 1 (19) Lysergic acid diethylamide;
- 2 (20) Marijuana;
- 3 (21) Parahexyl;
- 4 (22) Mescaline;
- 5 (23) Peyote;
- 6 (24) N-ethyl-3-piperidyl benzilate;
- 7 (25) N-methyl-3-piperidyl benzilate;
- 8 (26) Psilocybin;
- 9 (27) Psilocyn;
- 10 (28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
- 11 (29) Ethylamine analog of phencyclidine (PCE);
- 12 (30) Pyrrolidine analog of phencyclidine (PCPy, PHP);
- 13 (31) Thiophene analog of phencyclidine (TPCP; TCP);
- 14 (32) Gamma-butyrolactone, including butyrolactone;
- 15 butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
- 16 dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone;
- 17 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-
- 18 hydroxybutyric acid lactone; 3-hydroxybutyric acid
- 19 lactone and 4-hydroxybutanoic acid lactone with
- 20 Chemical Abstract Service number 96-48-0 when any such
- 21 substance is intended for human ingestion;



- 1 (33) 1,4 butanediol, including butanediol; butane-1,4-diol;  
2 1,4- butylenes glycol; butylene glycol; 1,4-  
3 dihydroxybutane; 1,4- tetramethylene glycol;  
4 tetramethylene glycol; tetramethylene 1,4- diol with  
5 Chemical Abstract Service number 110-63-4 when any  
6 such substance is intended for human ingestion;
- 7 (34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),  
8 its optical isomers, salts, and salts of isomers;
- 9 (35) N-benzylpiperazine (BZP; 1-benzylpiperazine) its  
10 optical isomers, salts, and salts of isomers;
- 11 (36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its  
12 optical isomers, salts, and salts of isomers;
- 13 (37) Alpha-methyltryptamine (AMT), its isomers, salts, and  
14 salts of isomers;
- 15 (38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its  
16 isomers, salts, and salts of isomers;
- 17 (39) Salvia divinorum;
- 18 (40) Salvinorin A;
- 19 (41) Divinorin A;



- 1 (42) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some  
2 trade or other names: 5-methoxy-3-[2-  
3 (dimethylamino)ethyl]indole; 5-MeO-DMT);
- 4 (43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
- 5 (44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
- 6 (45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
- 7 (46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
- 8 (47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-  
9 2);
- 10 (48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine  
11 (2C-T-4);
- 12 (49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 13 (50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
- 14 (51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
- 15 (52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-  
16 methoxybenzyl)ethanamine, its optical, positional, and  
17 geometric isomers, salts, and salts of isomers (Other  
18 names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
- 19 (53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-  
20 methoxybenzyl)ethanamine, its optical, positional, and



1 geometric isomers, salts, and salts of isomers (Other  
2 names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); and  
3 (54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-  
4 methoxybenzyl)ethanamine, its optical, positional, and  
5 geometric isomers, salts, and salts of isomers (Other  
6 names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36).

7 (e) Depressants. Unless specifically excepted, the  
8 schedule shall include any material, compound, mixture, or  
9 preparation which contains any quantity of the substance:

- 10 (1) Mecloqualone; or  
11 (2) Methaqualone.

12 (f) Stimulants. Unless specifically excepted or unless  
13 listed in another schedule, any material, compound, mixture, or  
14 preparation which contains any quantity of the following  
15 substances having a stimulant effect on the central nervous  
16 system, including its salts, isomers, and salts of isomers:

- 17 (1) Aminorex;  
18 (2) Cathinone;  
19 (3) Fenethylline;  
20 (4) Methcathinone;  
21 (5) N-ethylamphetamine;



- 1           (6) 4-methylaminorex;
- 2           (7) N,N-dimethylamphetamine; and
- 3           (8) Substituted cathinones, any compound, except bupropion
- 4           or compounds listed under a different schedule,
- 5           structurally derived from 2-aminopropan-1-one by
- 6           substitution at the 1-position with either phenyl,
- 7           naphthyl, or thiophene ring systems, whether or not
- 8           the compound is further modified in any of the
- 9           following ways:
- 10          (A) By substitution in the ring system to any extent
- 11           with alkyl, alkylenedioxy, alkoxy, haloalkyl,
- 12           hydroxyl, or halide substituents, whether or not
- 13           further substituted in the ring system by one or
- 14           more other univalent substituents;
- 15          (B) By substitution at the 3-position with an acyclic
- 16           alkyl substituent; or
- 17          (C) By substitution at the 2-amino nitrogen atom with
- 18           alkyl, dialkyl, benzyl, or methoxybenzyl groups,
- 19           or by inclusion of the 2-amino nitrogen atom in a
- 20           cyclic structure.



1           Some other trade names: Mephedrone (2-methylamino-1-  
2           p-tolylpropan-1-one), also known as 4-  
3           methylephedrone or MMCAT;  
4           Methylenedioxypyrovalerone (MDPV, MDPK); methylone or  
5           3,4-methylenedioxymethcathinone; and 1-  
6           (benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one,  
7           monohydrochloride, also known as Ethylone, bk-MDEA  
8           hydrochloride, MDEC; 3,4-Methylenedioxy-N-  
9           ethylcathinone; bk-Methylenedioxyethylamphetamine.

10           (g) Any of the following cannabinoids, their salts,  
11           isomers, and salts of isomers, unless specifically excepted,  
12           whenever the existence of these salts, isomers, and salts of  
13           isomers is possible within the specific chemical designation:

- 14           (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols  
15           naturally contained in a plant of the genus Cannabis  
16           (cannabis plant), as well as synthetic equivalents of  
17           the substances contained in the plant, or in the  
18           resinous extractives of Cannabis, sp. or synthetic  
19           substances, derivatives, and their isomers with  
20           similar chemical structure and pharmacological  
21           activity to those substances contained in the plant,



1           such as the following: Delta 1 cis or trans  
2           tetrahydrocannabinol, and their optical isomers; Delta  
3           6 cis or trans tetrahydrocannabinol, and their optical  
4           isomers; and Delta 3,4 cis or trans-  
5           tetrahydrocannabinol, and its optical isomers (since  
6           nomenclature of these substances is not  
7           internationally standardized, compounds of these  
8           structures, regardless of numerical designation of  
9           atomic positions, are covered);

10       (2) Naphthoylindoles; meaning any compound containing a 3-  
11       (1-naphthoyl)indole structure with substitution at the  
12       nitrogen atom of the indole ring by a alkyl,  
13       haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
14       1-(N-methyl-2-piperidiny)l)methyl or 2-(4-  
15       morpholinyl)ethyl group, whether or not further  
16       substituted in the indole ring to any extent and  
17       whether or not substituted in the naphthyl ring to any  
18       extent;

19       (3) Naphthylmethylinindoles; meaning any compound containing  
20       a 1H-indol-3-yl-(1-naphthyl) methane structure with  
21       substitution at the nitrogen atom of the indole ring





1 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
2 cycloalkylethyl, 1-(N-methyl-2-piperidiny) methyl or  
3 2-(4-morpholinyl) ethyl group whether or not further  
4 substituted in the indole ring to any extent and  
5 whether or not substituted in the naphthyl ring to any  
6 extent;

7 (4) Naphthoylpyrroles; meaning any compound containing a  
8 3-(1-naphthoyl)pyrrole structure with substitution at  
9 the nitrogen atom of the pyrrole ring by a alkyl,  
10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
11 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)  
12 ethyl group whether or not further substituted in the  
13 pyrrole ring to any extent, whether or not substituted  
14 in the naphthyl ring to any extent;

15 (5) Naphthylmethylindenes; meaning any compound containing  
16 a naphthylideneindene structure with substitution at  
17 the 3-position of the indene ring by a alkyl,  
18 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
19 1-(N-methyl-2-piperidiny) methyl or 2-(4-morpholinyl)  
20 ethyl group whether or not further substituted in the



1 indene ring to any extent, whether or not substituted  
2 in the naphthyl ring to any extent;

3 (6) Phenylacetylindoles; meaning any compound containing a  
4 3-phenylacetylindole structure with substitution at  
5 the nitrogen atom of the indole ring by a alkyl,  
6 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
7 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)  
8 ethyl group whether or not further substituted in the  
9 indole ring to any extent, whether or not substituted  
10 in the phenyl ring to any extent;

11 (7) Cyclohexylphenols; meaning any compound containing a  
12 2-(3-hydroxycyclohexyl) phenol structure with  
13 substitution at the 5-position of the phenolic ring by  
14 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
15 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or  
16 2-(4-morpholinyl) ethyl group whether or not  
17 substituted in the cyclohexyl ring to any extent;

18 (8) Benzoylindoles; meaning any compound containing a 3-  
19 (benzoyl) indole structure with substitution at the  
20 nitrogen atom of the indole ring by a alkyl,  
21 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,



1 1-(N-methyl-2-piperidiny)l methyl, or 2-(4-  
2 morpholinyl) ethyl group whether or not further  
3 substituted in the indole ring to any extent and  
4 whether or not substituted in the phenyl ring to any  
5 extent;

6 (9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)  
7 pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-  
8 naphthalenylmethanone (another trade name is WIN  
9 55,212-2);

10 (10) (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-  
11 methyloctan-2-yl)-6a,7,10,10a-  
12 tetrahydrobenzo[c]chromen-1-ol (Other trade names are:  
13 HU-210/HU-211);

14 (11) Tetramethylcyclopropanoylindoles; meaning any compound  
15 containing a 3-tetramethylcyclopropanoylindole  
16 structure with substitution at the nitrogen atom of  
17 the indole ring by an alkyl, haloalkyl, cyanoalkyl,  
18 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-  
19 methyl-2-piperidiny)l methyl, 2-(4-morpholinyl)ethyl,  
20 1-(N-methyl-2-pyrrolidiny)l methyl, 1-(N-methyl-3-  
21 morpholinyl) methyl, or tetrahydropyranylmethyl group,



whether or not further substituted in the indole ring  
to any extent and whether or not substituted in the  
tetramethylcyclopropyl ring to any extent;

(12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,  
its optical, positional, and geometric isomers, salts,  
and salts of isomers (Other names: APINACA, AKB48);

(13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its  
optical, positional, and geometric isomers, salts, and  
salts of isomers (Other names: PB-22; QUPIC);

(14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-  
carboxylate, its optical, positional, and geometric  
isomers, salts, and salts of isomers (Other names: 5-  
fluoro-PB-22; 5F-PB-22);

(15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-  
fluorobenzyl)-1H-indazole-3-carboxamide, its optical,  
positional, and geometric isomers, salts, and salts of  
isomers (Other names: AB-FUBINACA);

(16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-  
indazole-3-carboxamide, its optical, positional, and  
geometric isomers, salts, and salts of isomers (Other  
names: ADB-PINACA);



- (17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: AB-CHMINACA);
- (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, and geometric isomers, salts, and salts of isomers (Other names: AB-PINACA);
- (19) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone, and geometric isomers, salts, and salts of isomers (Other names: THJ-2201);
- (20) Methyl (1-(4-fluorobenzyl)-1 H-indazole-3-carbonyl)-L-valinate, and geometric isomers, salts, and salts of isomers (Other names: FUB-AMB);
- (21) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, and geometric isomers, salts, and salts of isomers (Other names: 5-fluoro-AMB, 5-fluoro-AMP);
- (22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, and geometric isomers, salts, and salts of isomers (Other names: AKB48 N-(5-



1 fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl  
2 analog, 5F-APINACA);

3 (23) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and  
4 geometric isomers, salts, and salts of isomers (Other  
5 names: STS-135, 5F-APICA; 5-fluoro-APICA);

6 (24) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-  
7 carboxylate, and geometric isomers, salts, and salts  
8 of isomers (Other names: NM2201);

9 (25) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-  
10 (cyclohexylmethyl)-1H-indazole-3-carboxamide, and  
11 geometric isomers, salts, and salts of isomers (Other  
12 names: MAB-CHMINACA and ADB-CHMINACA); and

13 (26) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-  
14 carboxamido]-3,3-dimethylbutanoate (Other names: 5F-  
15 ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical,  
16 positional, and geometric isomers, salts, and salts of  
17 isomers.

18 (h) The enumeration of cannabis, tetrahydrocannabinols, or  
19 chemical derivatives of these as schedule I controlled  
20 substances does not apply to the medical use of cannabis  
21 pursuant to section 329, part IX, and chapter 329D."



1       SECTION 3. Section 329-121, Hawaii Revised Statutes, is  
2 amended by amending the definition of "medical use" to read as  
3 follows:

4       ""Medical use" means the acquisition, possession,  
5 cultivation, use, distribution, or transportation of cannabis or  
6 paraphernalia relating to the administration of cannabis to  
7 alleviate the symptoms or effects of a qualifying patient's  
8 debilitating medical condition. For the purposes of "medical  
9 use", the state and federal schedulings of cannabis as a  
10 controlled substance do not apply. For the purposes of "medical  
11 use", the term distribution is limited to the transfer of  
12 cannabis and paraphernalia."

13       SECTION 4. New statutory material is underscored.

14       SECTION 5. This Act shall take effect upon its approval.

15       INTRODUCED BY:

*Will Eger*  
*David Thiel* *Ron E. Oki*  
*Mark*  
*Stacy*  
*Anna M. M. M. M.*



# S.B. NO. 2217

**Report Title:**

Medical Use of Cannabis; Decriminalization

**Description:**

Clarifies that medical use of cannabis is not considered to be a state or federal crime.

*The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.*

